CD274 and neoplasm: Additionally, as described in Section 3.2, PI3Kδ inhibitors can synergize with immune checkpoint blockers (ICBs, such as PD-1/PD-L1 inhibitors), providing a more robust and sustained anti-tumor response [78,125].